Aquestive Therapeutics, Inc. AQST Deferred Tax Liabilities
Deferred Tax Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilities.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s deferred tax liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s deferred tax liabilities?
- Aquestive Therapeutics, Inc. (AQST) reported deferred tax liabilities of $1.75M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred tax liabilities?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s deferred tax liabilities has grown at a 65.0% compound annual growth rate (CAGR), from $642K to $1.75M.
- What does deferred tax liabilities mean?
- Future tax obligations from temporary differences — most commonly accelerated tax depreciation that creates higher current tax deductions than book depreciation.